Home > Pulmonology > ERS 2020 > Asthma – What's New > Treatment according to genotype: The future of asthma therapy?

Treatment according to genotype: The future of asthma therapy?

Presented By
Dr Tom Ruffles, Brighton & Sussex Medical School, UK
Conference
ERS 2020
In the first study assessing personalised care, paediatric asthma patients seem to experience a small benefit in their quality of life when treated according to their rs1042713 genotype [1]. Drugs do not work the same in every patient. “Even if there are several reasons, like non-compliance, there are still people who do not respond. With our study, we wanted to find out whether variations in the gene status have an influence on the efficacy of a drug,” said Dr Tom Ruffles (Brighton & Sussex Medical School, UK). The study included 241 children aged 12-18 years from England and Scotland. Asthma genetic differences were determined using a saliva sample: researchers looked for 1 or 2 copies of an altered gene of the β2 receptor. Participants were randomised to personalised care (i.e. rs1042713 genotype-based prescribing) or standard care according to existing guidelines. A 4-week run-in period was followed by a 12-month treatment and follow-up pha...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on